Open AccessEtravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age
Author(s) -
Taiju Miyagami,
Richard M. Rutstein,
Andrew Wiznia,
Bobbie Graham,
Carmelita Alvero,
Lee Fairlie,
Kathryn Lypen,
Kathleen George,
Ellen Townley,
Jack Moye,
Diane Costello,
Christina Reding,
Cristina Barroso Hofer,
Herta Crauwels,
Xavier Woot de Trixhe,
Lotke Tambuyzer,
Simon Vanveggel,
Magda Opsomer,
Jennifer J. Kiser
Publication year - 2021
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002902
Subject(s) - pharmacokinetics , medicine , cohort , etravirine , adverse effect , human immunodeficiency virus (hiv) , ritonavir , cohort study , antiretroviral therapy , pediatrics , gastroenterology , viral load , virology
To describe the pharmacokinetics, safety, and efficacy of etravirine (ETR) in HIV-infected children 1 to less than 6 years of age.